Safety and efficacy of natalizumab in children with MS

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

Safety and efficacy of natalizumab in children with MS

Postby MSUK » Thu Sep 16, 2010 5:56 am

Image

Abstract

OBJECTIVE: To describe the effect of natalizumab in the treatment of subjects with active multiple sclerosis (MS) treated before the age of 18 years.

METHODS: Nineteen paediatric subjects with MS (mean age 14.6 2.2 years, mean number of attacks 5.2 1.9 during the pretreatment phase of 27.7 19.7 months, median pretreatment Expanded Disability Status Scale score [EDSS] 2.5, range 1.0-5.0) were treated with natalizumab at the dose of 300 mg every 28 days. After treatment initiation, patients were reassessed clinically every month; brain MRI was performed at baseline and every 6 months.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1408
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 1980
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to Tysabri (Antegren or Natalizumab)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users